Moreover, a national Alliance-sponsored cooperative group phase II clinical trial evaluated the efficacy of SMO, AKT1, and FAK inhibitors for recurrent or progressive meningiomas with targetable alterations in SMO, AKT1, and NF2, respectively (NCT02523014/A071401) (5). Here, AKT1 is linked to meningioma.